Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingwei Fucha
- Development stage
- Unknown
- Lead developer
- Shaanxi Provincial People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Jingwei Fucha is a traditional fermented dark tea (Fuzhuan tea) originating from Shaanxi Province, China, characterized by the presence of the probiotic fungus *Eurotium cristatum*, commonly known as Golden Flowers. Developed as a functional beverage with therapeutic potential, research conducted by institutions such as Shaanxi Provincial People's Hospital has focused on its application in cardiovascular health, particularly for coronary heart disease and metabolic syndrome. The tea contains a complex profile of bioactive compounds, including theabrownins, tea polyphenols, and polysaccharides, which work synergistically to modulate gut microbiota, improve lipid metabolism, and exert potent antioxidant and anti-inflammatory effects. Clinical studies suggest that regular consumption may improve vascular endothelial function and reduce oxidative stress markers in patients with coronary artery disease.
- Brand names
- Jingwei Fucha
- Other names
- Jingwei Fuzhuan TeaShaanxi Fuzhuan TeaJingwei Dark Tea
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Jingwei Fucha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jingwei Fucha.